-- Oral presentation showcased previously disclosed data that demonstrate setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in 12 patients ages 2-
Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting
On 6ix: 6ix.com/news/rhythm-pharmaceuticals-presents-data-from-phase-3-pediatrics-trial-at-pediatric
Watch Rhythm Pharmaceuticals' latest callRhythm Pharmaceuticals (NASDAQ:RYTM) Q3 2026 Earnings Call · Replay · Nov 3Read the transcript of Rhythm Pharmaceuticals (NASDAQ:RYTM) Q3 2026 Earnings CallRhythm Pharmaceuticals, Inc. on 6ix
In the deck
Story so far
- Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek® 2023
- Rhythm Pharmaceuticals Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023
- Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity at ObesityWeek® and Plans to Initiate Phase 3 Trial in Early 2023
Earlier from Rhythm Pharmaceuticals
- Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology
- Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
- Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
- Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
- Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Later from Rhythm Pharmaceuticals
- Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
- Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
- Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
- Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024
- Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency
Follow Rhythm Pharmaceuticals into a list and get an email when it puts out news.
Follow Rhythm Pharmaceuticals